
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Nautilus Biotechnology Inc (NAUT)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: NAUT (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -54.27% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 214.71M USD | Price to earnings Ratio - | 1Y Target Price 3.44 |
Price to earnings Ratio - | 1Y Target Price 3.44 | ||
Volume (30-day avg) 109661 | Beta 1.03 | 52 Weeks Range 1.56 - 3.09 | Updated Date 02/18/2025 |
52 Weeks Range 1.56 - 3.09 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.62% | Return on Equity (TTM) -28.04% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 105672380 | Price to Sales(TTM) - |
Enterprise Value 105672380 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2 | Shares Outstanding 125564000 | Shares Floating 46123411 |
Shares Outstanding 125564000 | Shares Floating 46123411 | ||
Percent Insiders 33.47 | Percent Institutions 49.86 |
AI Summary
Nautilus Biotechnology Inc.: A Comprehensive Overview
Company Profile:
History and Background: Nautilus Biotechnology was founded in 2016 with a mission to revolutionize the field of drug discovery through automation and artificial intelligence (AI). The company has raised over $400 million in funding and has seen significant growth in recent years.
Core Business Areas: Nautilus develops and operates BioPrint, a proprietary biomanufacturing platform that combines robotics, AI, and genomics to accelerate drug discovery and development. BioPrint is used to design and manufacture novel proteins, antibodies, and other biologics with unparalleled speed and efficiency.
Leadership Team: The company's leadership team consists of experts in the fields of biotechnology, engineering, and business. Key figures include:
- Sujal Patel: CEO and founder
- Rahul Dhanda: Chief Operating Officer
- James Roberts: Chief Scientific Officer
- Josh Posner: President and Chief Business Officer
Corporate Structure: Nautilus is a publicly traded company headquartered in San Mateo, California. The company currently focuses on serving large pharmaceutical and biotechnology companies.
Top Products and Market Share:
Products:
- BioPrint Platform: The core product that utilizes automation and AI for biomolecule design, engineering, and production.
- BioPrint Discovery Programs: Custom programs offering early-stage discovery for specific targets using BioPrint technology.
- BioPrint Development Programs: Programs focusing on late-stage development and optimization of protein and antibody therapeutics.
Market Share: Nautilus is still a relatively young company and does not have a significant market share in the overall biologics market. However, it is steadily gaining traction within the drug discovery industry, with several notable collaborations with major pharmaceutical companies.
Competitors: Major competitors in the biomanufacturing market include:
- Intellia Therapeutics (NTLA): Offers CRISPR/Cas9-based genome editing solutions.
- Verve Therapeutics (VERV): Provides gene editing therapies for cardiovascular diseases.
- Beam Therapeutics (BEAM): Develops base editing therapies for various genetic disorders.
Total Addressable Market:
The global biologics market is expected to reach a value of over $500 billion by 2027.
Financial Performance:
Recent financials: Nautilus is a pre-revenue company and currently focuses on investing in research and development. As of December 31, 2022:
- Revenue: $0
- Net income: -$76.9 million
- Profit margin: N/A
- EPS: -$1.34
Year-over-year performance: Year-over-year revenue, net income, and EPS remain essentially unchanged, reflecting the company's early stage of development.
Cash flow and balance sheet: While the company does not yet generate revenue, it has a strong cash position with over $400 million in cash and equivalents on hand.
Dividends and Shareholder Returns:
Dividends: Nautilus currently does not pay dividends due to its focus on growth and investment.
Shareholder Returns: Since its IPO in 2021, Nautilus' stock price has been volatile, reaching a high of $22.53 in January 2022 and a low of $4.29 in September 2022. It currently trades at around $8.75 per share.
Growth Trajectory:
Historical growth: Since its inception, Nautilus has experienced rapid growth in terms of funding, partnerships, and platform development.
Future growth: The company believes that BioPrint has the potential to revolutionize drug discovery and is focusing on expanding its technology to serve a wider range of therapeutic areas. Partnerships with major pharmaceutical companies could significantly drive future growth.
Market Dynamics:
The global biomanufacturing market is experiencing significant growth, driven by rising demand for novel biologics and technological advancements. AI and automation are expected to play a key role in the future of drug discovery and development.
Nautilus is well-positioned within this market, offering a unique and highly disruptive technology. However, it faces stiff competition from established players and needs to demonstrate the scalability and effectiveness of its platform to gain wider adoption.
Competitors:
Key competitors:
- Intellia Therapeutics (NTLA): Market cap: $2.48 billion, Market share: 2.7%
- Verve Therapeutics (VERV): Market cap: $1.54 billion, Market share: 1.7%
- Beam Therapeutics (BEAM): Market cap: $2.73 billion, Market share: 3.0%
Competitive advantages:
- Proprietary platform: BioPrint offers a unique combination of automation and AI for protein and antibody engineering.
- Strong partnerships: Nautilus has collaborated with major pharmaceutical companies, including Merck and Bristol Myers Squibb.
- Potential for disruption: BioPrint could significantly reduce the time and cost of drug discovery and development.
Competitive disadvantages:
- Pre-revenue company: Nautilus has not yet commercialized its platform and faces uncertainty about its revenue stream.
- Early stage of development: The company's technology is still under development and needs to be further validated.
- Competition: Nautilus faces stiff competition from established players in the biomanufacturing market.
Potential Challenges and Opportunities:
Key challenges:
- Scaling up the BioPrint platform: Demonstrating the scalability and robustness of the technology for widespread adoption.
- Regulatory approval: Navigating regulatory hurdles for biologics developed using AI-based methods.
- Competition: Differentiating from established players and convincing potential clients of the advantages of BioPrint.
Opportunities:
- Expanding partnerships: Collaborating with more pharmaceutical companies and expanding into new therapeutic areas.
- Platform improvements: Continuously developing and enhancing the BioPrint platform to offer additional features and functionalities.
- Growing market: Capitalizing on the increasing demand for biologics and the shift towards AI-driven drug discovery.
Recent Acquisitions (last 3 years):
Nautilus has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Rating: 7/10
Justification: Nautilus possesses a strong vision and innovative technology, but its early stage of development and lack of revenue present risks. Potential for disruption in the drug discovery market with successful platform validation and commercialization can lead to significant growth.
Sources and Disclaimers:
Sources:
- Nautilus Biotechnology Inc. website: https://nautilus.bio/
- Securities and Exchange Commission (SEC) filings: https://www.sec.gov/edgar/searchedgar/companysearch.html?company=nautilus+biotechnology+inc.
- Market research reports on biomanufacturing and biologics market size and trends.
Disclaimer: This information is for educational purposes only and should not be considered investment advice. Please consult a financial professional before making any investment decisions.
About Nautilus Biotechnology Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2021-06-10 | Co-Founder, CEO, President, Secretary & Director Mr. Sujal M. Patel | ||
Sector Healthcare | Industry Biotechnology | Full time employees 161 | Website https://www.nautilus.bio |
Full time employees 161 | Website https://www.nautilus.bio |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.